Beraprost

Generic Name: Beraprost

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₂₄H_₃₀O_₅

CAS Number: 88430-50-6

Unique Ingredient Identifier: 35E3NJJ4O6

Background: Beraprost is a synthetic analogue of prostacyclin, under clinical trials for the treatment of pulmonary hypertension. It is also being studied for use in avoiding reperfusion injury.

Indication: For the treatment of pulmonary hypertension.

Associated Conditions: Cystic Fibrosis (CF), Pain, Ulcers, Sensations of cold

Associated Therapies: -

Clinical Trials

Efficacy and Safety of Dorner Tablets and Aspirin for Prevention of Arteriosclerosis Progress in Type 2 Diabetes Mellitus Patients

Phase 4

Terminated

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: Beraprost
Drug: Aspirin

First Posted Date: 2016-06-01

Last Posted Date: 2016-06-21

Lead Sponsor: Astellas Pharma Inc

Target Recruit Count: 190

Registration Number: NCT02786979

Locations: 🇨🇳
Site CN00006, Tianjin, Tianjin, China
🇨🇳
Site CN00001, Beijing, Beijing, China
🇨🇳
Site CN00003, Shanghai, Shanghai, China

and more 3 locations

TRK-100STP PhaseII Clinical Study -Chronic Renal Failure (Primary Glomerular Disease/Nephrosclerosis)

Phase 2

Completed

Conditions: Renal Insufficiency, Chronic

Interventions: Drug: Placebo
Drug: Beraprost

First Posted Date: 2015-06-24

Last Posted Date: 2015-06-29

Lead Sponsor: Toray Industries, Inc

Target Recruit Count: 113

Registration Number: NCT02480751

Prev
1
Next

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy